Prognostic Significance of 3-Month Prostate-specific Antigen Level Following Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer.

Abstract

BACKGROUND/AIM:

We examined the prognostic use of the 3-month prostate-specific antigen (PSA3m) level after androgen-deprivation therapy in patients with de novo metastatic hormone-sensitive prostate cancer (mHSPC).

PATIENTS AND METHODS:

The present study included 145 patients with mHSPC who received primary androgen-deprivation therapy.

RESULTS:

The optimal cutoff PSA3m value for prediction of 5-year overall survival was 2.56 ng/ml (area under the receiver operating characteristics curve=0.67) using a time-dependent receiver operating characteristic (survival ROC) curve. In patients with CHAARTED low-volume and LATITUDE low-risk disease, the median overall survival was longer for patients with low PSA3m than that for those with high PSA3m. Multivariate analysis revealed PSA3m (hazard ratio=1.99; p=0.006) and age ≥80 years as independent risk factors for overall survival in patients with mHSPC.

CONCLUSION:

PSA3m can be a useful prognostic biomarker to avoid excessive upfront combination therapy, particularly in elderly patients with low-volume and low-risk mHSPC.

• Authors: Yujiro Nagata, Takuo Matsukawa, Ikko Tomisaki, Naohiro Fujimoto
• Journal: Anticancer research (Anticancer Res) Vol. 42 Issue 2 Pg. 1107-1114 (Feb 2022) ISSN: 1791-7530 [Electronic] Greece
• PMID: 35093913 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Androgen Antagonists
• Prostate-Specific Antigen

Topics

• Adenocarcinoma (diagnosis, drug therapy, mortality, pathology)
• Aged
• Aged, 80 and over
• Androgen Antagonists (therapeutic use)
• Follow-Up Studies
• Humans
• Japan (epidemiology)
• Male
• Middle Aged
• Neoplasm Metastasis
• Predictive Value of Tests
• Prognosis
• Prostate-Specific Antigen (analysis, blood)
• Prostatic Neoplasms (diagnosis, drug therapy, mortality, pathology)
• Survival Analysis
• Time Factors
• Treatment Outcome